Prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in lymphoma: a systematic review and meta-analysis.
Yangyang DingCheng SunLinhui HuShu-Dao XiongZhimin ZhaiPublished in: Annals of hematology (2023)
Previous studies on the prognostic value of soluble programmed cell death ligand 1 (sPD-L1) in lymphoma patients have yielded inconsistent results. Here, we conducted a meta-analysis and systematic review to investigate the prognostic significance of sPD-L1 in lymphoma, especially in diffuse large B-cell lymphoma (DLBCL) and NK/T-cell lymphoma (NK/TCL). A total of 11 studies with 1185 patients were included in the meta-analysis, and the combined results indicated that high sPD-L1 levels were associated with worse overall survival (OS) (HR = 2.27, 95%CI: 1.70-3.04) and progression-free survival (PFS) (HR = 2.68, 95%CI: 1.92-3.75). Furthermore, subgroup analysis showed that sPD-L1 remained a significant prognostic factor for OS. The meta-analysis indicated that sPD-L1 may be a potential prognostic biomarker for lymphoma, especially in DLBCL and NK/TCL, and high sPD-L1 levels were associated with worse survival prognosis.
Keyphrases
- diffuse large b cell lymphoma
- systematic review
- prognostic factors
- epstein barr virus
- end stage renal disease
- meta analyses
- free survival
- chronic kidney disease
- newly diagnosed
- ejection fraction
- case control
- peritoneal dialysis
- randomized controlled trial
- clinical trial
- nk cells
- patient reported outcomes
- study protocol